Cargando…

Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study

INTRODUCTION: The dipeptidyl peptidase-4 (DPP-4) enzyme significantly influences carcinogenic pathways in the skin. The objective of this study was to determine whether DPP-4 inhibitors are associated with the incidence of melanoma and nonmelanoma skin cancer, compared with sulfonylureas. RESEARCH D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pradhan, Richeek, Yu, Oriana H Y, Platt, Robert W, Azoulay, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Epidemiology/Health services research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649616/ https://www.ncbi.nlm.nih.gov/pubmed/37949470 http://dx.doi.org/10.1136/bmjdrc-2023-003550

Ejemplares similares

Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
por: Sütő, Gábor, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
por: Abrahami, Devin, et al.
Publicado: (2018)

Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK
por: Gonzalez Perez, Antonio, et al.
Publicado: (2023)

Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study
por: Pradhan, Richeek, et al.
Publicado: (2022)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK
por: González-Pérez, Antonio, et al.
Publicado: (2021)

Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol
por: Butterly, Elaine, et al.
Publicado: (2022)

Time trends in the incidence of clinically diagnosed type 2 diabetes and pre-diabetes in the UK 2009–2018: a retrospective cohort study
por: Pal, Kingshuk, et al.
Publicado: (2021)

Risk of 16 cancers across the full glycemic spectrum: a population-based cohort study using the UK Biobank
por: Rentsch, Christopher T, et al.
Publicado: (2020)

Associations between grip strength and incident type 2 diabetes: findings from the UK Biobank prospective cohort study
por: Boonpor, Jirapitcha, et al.
Publicado: (2021)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Medication burden in the first 5 years following diagnosis of type 2 diabetes: findings from the ADDITION-UK trial cohort
por: Black, James A, et al.
Publicado: (2015)

Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records
por: Aslam, Aisha A., et al.
Publicado: (2022)

Contribution of type 2 diabetes to all-cause mortality, cardiovascular disease incidence and cancer incidence in white Europeans and South Asians: findings from the UK Biobank population-based cohort study
por: Muilwijk, Mirthe, et al.
Publicado: (2019)

Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
por: Liao, Wen-Ling, et al.
Publicado: (2017)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Inequalities in glycemic management in people living with type 2 diabetes mellitus and severe mental illnesses: cohort study from the UK over 10 years
por: Das-Munshi, Jayati, et al.
Publicado: (2021)

Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Tissue inhibitor matrix metalloproteinase 1 and risk of type 2 diabetes in a Chinese population
por: Wang, Yeli, et al.
Publicado: (2020)

Night Shift Work, Genetic Risk, and Type 2 Diabetes in the UK Biobank
por: Vetter, Céline, et al.
Publicado: (2018)

Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
por: Jang, Yun-Mi, et al.
Publicado: (2011)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study
por: Wvan der Zanden, Rogier, et al.
Publicado: (2015)

Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study
por: Abrahami, Devin, et al.
Publicado: (2020)

Gestational diabetes and long-term risk for dyslipidemia: a population-based historical cohort study
por: Chodick, Gabriel, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Ethnic variation in the conversion of prediabetes to diabetes among immigrant populations relative to Canadian-born residents: a population-based cohort study
por: Fazli, Ghazal S, et al.
Publicado: (2020)

Ethnic disparities in progression rates for sight-threatening diabetic retinopathy in diabetic eye screening: a population-based retrospective cohort study
por: Olvera-Barrios, Abraham, et al.
Publicado: (2023)

Maternal diabetes and the risk of feeding and eating disorders in offspring: a national population-based cohort study
por: Wang, Hui, et al.
Publicado: (2020)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
por: Shoombuatong, Watshara, et al.
Publicado: (2015)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
por: Yazbeck, R., et al.
Publicado: (2021)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

Barriers and enablers to diabetic retinopathy screening: a cross-sectional survey of young adults with type 1 and type 2 diabetes in the UK
por: Prothero, Louise, et al.
Publicado: (2022)

Explaining the Decline in Early Mortality in Men and Women With Type 2 Diabetes: A population-based cohort study
por: Charlton, Judith, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0598hvam5a8t7t9op0jv999n18